InMode Ltd.
INMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframePart of the healthcare sector, InMode Ltd. (INMD) is listed under Medical Devices. The $803.9M market capitalization puts INMD squarely in small-cap range for its industry. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Market Cap
$803.9M
Beta
2.03
P/E (TTM)
11.55
P/E (Fwd)
10.18
EPS (TTM)
$1.21
EPS (Fwd)
$1.37
ROE
12.3%
ROA
6.2%
Cash
$501.1M
Total Debt
$4.5M
Free CF
$47.4M
52W Change
-10.7%
Annual Financials
Cash vs Debt
Where INMD stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, INMD finished 0.21% below its 150-day moving average ($14.35) and 0.42% below its 200-day moving average ($14.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INMD overbought or oversold?
At the October 16, 2026 close, INMD's RSI(14) was 53.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
InMode Ltd. holds $501.1M in cash against $4.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $47.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 12.3% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $454.3M (2022) to $370.5M (2025), a 18% decline worth watching.
A beta of 2.03 means INMD is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing INMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.